Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic appoints biopharmaceutical executive Jon Congleton to board
08:55am, Tuesday, 31'st Mar 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
06:30am, Tuesday, 31'st Mar 2026
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in t
Immunic appoints biopharmaceutical executive Jon Congleton to board
04:54am, Tuesday, 31'st Mar 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the...
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets
05:12pm, Tuesday, 24'th Mar 2026
On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes.
Immunic secures European patent for MS drug candidate vidofludimus calcium
08:38am, Tuesday, 10'th Mar 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for its experimental multiple sclerosis treatment vidofludimus calcium,
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
06:30am, Tuesday, 10'th Mar 2026
– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludim
Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)
01:14am, Wednesday, 04'th Mar 2026
Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the tw
Immunic to present at healthcare investor conferences in March
08:02am, Tuesday, 03'rd Mar 2026
Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief
UBS raises memory chip price targets as supply crunch deepens, defying sector sell-off
07:28am, Tuesday, 03'rd Mar 2026
The bank now forecasts DDR contract prices rising 72% in the first quarter alone, with undersupply expected to persist into 2028 Wall Street's retreat from...
Immunic to Participate in Investor Conferences in March
06:30am, Tuesday, 03'rd Mar 2026
NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal disea
FTSE 100 Live: London sell-off may be 'muted' as markets react to Iran war
02:57am, Monday, 02'nd Mar 2026
7.56am: IHG included in hotel competition probe The Competition and Markets Authority has launched an investigation into Intercontinental Hotels,...
Immunic secures $400M to support late-stage MS trials - ICYMI
03:16pm, Saturday, 28'th Feb 2026
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential
Immunic secures $400M to support late-stage MS trials - ICYMI
10:00am, Saturday, 28'th Feb 2026
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage...
Immunic sets stage for phase 3 MS data readout after $400M financing
09:03am, Thursday, 26'th Feb 2026
Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage develop
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
06:30am, Thursday, 26'th Feb 2026
– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Pote
